AstraZeneca Plc has disclosed data from its Phase 3 trial of the lung cancer drug Tagrisso (osimertinib) after the trial was stopped in April because of strong efficacy signals. Tagrisso is a tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR). The Phase 3 trial, called ADAURA, was treating patients with early-stage disease.
